2026 Interim report
Filed with HKEX · Stock code 6628 · · 77 pages · English
Corporate Information 2 Financial Highlights 4 Business Highlights 5 Management Discussion and Analysis 12 Other Information 37 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 53 Interim Condensed Consolidated Statement of Financial Position 54 Interim Condensed Consolidated Statement of Changes In Equity 56 Interim Condensed Consolidated Statement of Cash
Transcenta Holding Limited on 6ix
Earlier from Transcenta
- Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer
- Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform
- Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
- Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics
- Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
Later from Transcenta
- Notification letter and reply form to registered holders
- Notification letter and request form to non-registered holders
- Cancellation and grant of award pursuant to the share incentive scheme
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement-business update on the grant of China invention patents related to osemitamab (TST001) and its companion diagnostic antibody
Follow Transcenta into a list and get an email when it puts out news.
Follow Transcenta